Maximize Investment Impact with Engager & Multispecific Innovation
September 30-October 1 | Boston, MA
Driving high ROI across immune cell engagers through strategic partnerships & investments, capitalizing on novel targets & asset tunability to initiate competitive development programs across oncology & immunology
Confirmed to Attend:
Why Attend?
The Immune Cell Engager Partnering & Investment Summit is here. As part of the game-changing Partnering & Investment Series, it's the first-ever partnering forum for next-gen engager deal-making. It brings together top biotech companies leading engager and multispecific innovation, pharma leaders, and investors for hyper-aligned and more efficient business networking.
Unite with other immune cell engager business development leaders where cutting-edge science meets strategic networking to:
- Capitalize on protected face-to-face networking with a 100% aligned audience and the One-on-One Partnering platform, to efficiently generate higher-yielding deal opportunities and nurture multiple key relationships in a less competitive forum
- Understand assessment criteria, data package expectations, and due diligence of pharma and investors, and hear invaluable feedback into your financing or development programs
- Evaluate the total landscape of emerging engager assets to refine your points of differentiation, discuss collaboration and licensing options with similar stakeholders seeking creative partnerships to validate technologies or de-risk asset development
“Since the conference 6 months ago we are already working with one contact and we're about to sign another. We're already making compounds they want to test. The whole format was extremely useful. It's rare to just jump into a conference and come out with traction.” Biotech Chief Executive Officer, ADC Partnering & Investment Summit, 2024
EXPERT SPEAKERS INCLUDE
Venky Raghavan
Executive Director, Search & Evaluation, Oncology
Novartis
Sarah Holland
Chief Business Officer
CDR-Life
Annie Vemu
Senior Associate
Longwood Fund
Andy Meyer
Chief Business Officer
Janux Therapeutics
Nikhil Mutyal
Executive Director and Head of Search & Evaluation, R&I
AstraZeneca
Christopher Tan
Executive Director, Search & Evaluation, Business Development, Licensing, Infectious Diseases, Vaccines & Oncology
Merck
Saifur Rahman
Director, Search & Evaluation Immunology
Sanofi
Shiva Bolourchi
Executive Director, Head of Corporate Strategy & Partnerships
Marengo Therapeutics
Ross Castillo
Principal, Biotech Private Investments
Wellington Management Company
Tim Lu
Chief Medical Officer & Chief Scientific Officer
Candid Therapeutics
Networking Format
Pharma & Investor Icebreaker Sessions
Understand Interests Ahead of Meetings, to Present Insights Buyers Want
Don't miss opening pharma and investor icebreaker panels where Immunology Search & Evaluation, and Investment leads share context into expectations for data packages, stage of assets, targets of interest, and future deal-making trends. Understand nuances between buyers' interests to see who you align best with or start your 1-to-1 meeting from an advantage point, leading with information that matches these insights into buyers' interests
HIGH VALUE NETWORKING FORMATS
Select Your Pharma, Sit at Their Table
To protect the opportunity for biotech to sit in front of the attending pharma leads, the pharma icebreaker roundtables follow the opening panel. Across 90 minutes of networking time, biotech select to sit at multiple pharma tables, ensuring the opportunity to ask questions, give introductions, and set context into pipelines or platforms in return
Meet Investors, Share your Business Card
To maximize the number of investors you can connect with, the icebreaker speed networking following the venture and investment panel ensures you can swap business cards with all investors present. Join a high table and stay through short rounds of face-to-face investor introductions to ensure those relevant to your company stage, know who you are and can take your business card
Individual Meetings: One-on-One Partnering™
Schedule Meetings in Advance, with the Industry's Best Partnering Portal
Prepare and pre-arrange your most important meetings by reviewing the full attendee list, and company profiles and reaching out to fill your meeting calendar in advance. Guarantee 30-minute, 1-2-1, and face-to-face time, with pharma present in 70% of meetings and a 30% acceptance rate versus industry standard*
*Statistics an average from 2024 and 2025 Partnering & Investment Summits by Hanson Wade
Testimonials
"This was a brilliant opportunity to connect with potential partners and hear meaningful talks and discussions relevant to the space."
"The event assembled a diverse set of stakeholders extremely relevant in ADC & RLT partnering, including pharma BD, investors, and biotech executives. It was the right size (~100 attendees) that created organic opportunities for connections"